The Problem
Approximately 70% of cancers are not addressable with current targeted therapies. While CAR-T therapies have transformed hematological oncology, their application to solid tumors is limited by the absence of tumor-exclusive antigens.
Single-antigen CAR-T designs activate in the presence of low-level antigen expression on healthy tissue, leading to off-tumor toxicity and an industry-wide development bottleneck.
GoCART Recognition Dimer Platform
True AND-Gate Logic
GoCART employs a recognition dimer architecture that requires simultaneous engagement of two antigens on the same cell to trigger T-cell activation.
High Sensitivity Without Compromise
Unlike existing Boolean CAR designs, the platform preserves high-affinity binding while enforcing strict spatial coincidence, enabling physiological antigen detection.
Modular and Scalable
Binder modules are tunable and interchangeable, allowing rapid extension to new antigen pairs and disease indications.
Decentralized Science Model
GoCART integrates a token-governed research structure using legally binding Sponsored Research Agreements to coordinate funding, IP ownership, and community participation.
- Token-based governance of intellectual property
- Transparent allocation of research capital
- Open collaboration on non-sensitive scientific outputs
Leadership
Henry Erdlei, MD
Chief Executive Officer
Background in translational tumor immunology with medical training at Charité and doctoral research at the Max Delbrück Center.
Arailym Myrzagaliyeva
Chief Technology Officer
Experience in synthetic biology, molecular biotechnology, and global health initiatives, including leadership roles in academic-industry partnerships.
Chase Blakeley
Chief Operating Officer
Oversees operational execution, funding strategy, and partnerships with prior experience at Oracle and Tesla.
Development Roadmap
- 2025: In-vitro proof-of-concept and binder validation
- 2026: In-vivo preclinical studies and patent filings
- 2027+: GMP manufacturing preparation and IND-enabling studies